12%OFF
Fragment-based Drug Discovery: Lessons and Outlook
Daniel A. Erlanson
€ 169.43
€ 149.55
FREE Delivery in Ireland
Description for Fragment-based Drug Discovery: Lessons and Outlook
Hardback. The secret of success in drug discovery written by the pioneers in the field with unrivaled experience in fragment-based methods. In this handbook, the first-hand knowledge imparted by the world's leading experts provides a comprehensive overview of current methods and applications of fragment-based discovery. Editor(s): Erlanson, Daniel A.; Jahnke, Wolfgang; Mannhold, Raimund; Kubinyi, Hugo; Folkers, Gerd. Series: Methods and Principles in Medicinal Chemistry. Num Pages: 528 pages. BIC Classification: PN; TDCW. Category: (P) Professional & Vocational. Dimension: 245 x 176 x 30. Weight in Grams: 1318.
From its origins as a niche technique more than 15 years ago, fragment-based approaches have become a major tool for drug and ligand discovery, often yielding results where other methods have failed. Written by the pioneers in the field, this book provides a comprehensive overview of current methods and applications of fragment-based discovery, as well as an outlook on where the field is headed.
The first part discusses basic considerations of when to use fragment-based methods, how to select targets, and how to build libraries in the chemical fragment space. The second part describes established, novel and emerging methods for ... Read more
Show LessProduct Details
Format
Hardback
Publication date
2016
Publisher
Wiley-VCH Verlag GmbH Germany
Number of pages
528
Condition
New
Series
Methods and Principles in Medicinal Chemistry
Number of Pages
528
Place of Publication
Berlin, Germany
ISBN
9783527337750
SKU
V9783527337750
Shipping Time
Usually ships in 4 to 8 working days
Ref
99-1
About Daniel A. Erlanson
Daniel A. Erlanson is the co-founder and President of Carmot Therapeutics, Inc., which is developing fragment-based approaches to address unmet needs in drug discovery. Prior to Carmot, Dr. Erlanson worked in medicinal chemistry and technology development at Sunesis Pharmaceuticals, which he joined at the company's inception. Before Sunesis, he was an NIH postdoctoral fellow with Dr. James A. Wells at ... Read more
Reviews for Fragment-based Drug Discovery: Lessons and Outlook